A Phase I Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral CUDC-427, an Antagonist of Inhibitors of Apoptosis (IAP) Proteins, When Administered Twice Daily in Subjects With Advanced and Refractory Solid Tumors or Lymphoma

Trial Profile

A Phase I Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral CUDC-427, an Antagonist of Inhibitors of Apoptosis (IAP) Proteins, When Administered Twice Daily in Subjects With Advanced and Refractory Solid Tumors or Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs CUDC 427 (Primary)
  • Indications Diffuse large B cell lymphoma; Lymphoma; Marginal-zone-B-cell-lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Curis; Genentech
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 13 Apr 2016 Status changed from recruiting to completed, as per results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 13 Apr 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top